MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, KAPA had -$816K decrease in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
-$816K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from the at the market ...
    • Fair value of vested restricted ...
    • Amortization of vendor advances
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Payment of deferred offering cos...
    • Prepaid expenses and other curre...

Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net loss
-1,654 -1,365 -1,398 -2,684
Amortization of intangible asset
40 40 40 80
Debt discount amortization
-0 0 0
Fair value of common shares issued in connection with the conversion of accounts payable
-0 0 -
Fair value of warrants issued in connection with convertible notes payable
-0 0 -
Gain on settlement of accounts payable
-0 --
Vendor advances
-0 0 -
Amortization of vendor advances
220 212 660 1,298
Fair value of vested restricted stock units
259 259 70 153
Prepaid expenses and other current assets
92 27 -64 50
Accounts payable and accrued expenses
191 -203 -274 -316
Net cash used in operating activities
-1,036 -1,084 -838 -1,519
Proceeds from common stock issued for cash in connection with the closing of the initial public offering
-0 0 -
Proceeds from notes payable - officers
-0 0 0
Proceeds from the equity line of credit
-0 3,379 223
Proceeds from the sale and exercise of prefunded warrants
-0 0 3,058
Proceeds from the at the market (atm) offering
385 ---
Payment of deferred offering costs
165 0 0 0
Net increase in cash and cash equivalents
--1,084 --
Net cash provided by financing activities
220 0 3,379 3,281
Net increase (decrease) in cash and cash equivalents
-816 -1,084 2,541 1,762
Cash and cash equivalents, beginning of period
4,491 5,575 1,272 -
Cash and cash equivalents, end of period
3,675 4,491 5,575 -
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from the at themarket (atm) offering$385K Net cash provided byfinancing activities$220K Canceled cashflow$165K Net increase(decrease) in cash and cash...-$816K Canceled cashflow$220K Fair value of vestedrestricted stock units$259K Amortization of vendoradvances$220K Accounts payable andaccrued expenses$191K Amortization of intangibleasset$40K Payment of deferredoffering costs$165K Net cash used inoperating activities-$1,036K Canceled cashflow$710K Net loss-$1,654K Prepaid expenses andother current assets$92K

Kairos Pharma, LTD. (KAPA)

Kairos Pharma, LTD. (KAPA)